Divi's Laboratories: Sharekhan reiterates Buy recommendation with price target of Rs 4500
Divi's Laboratories is expected to benefit from strong growth likely in the global active pharmaceutical ingredients (API) space, driven by multiple factors. Increasing preference for biologics for disease management, key drugs going off patent, outsourcing opportunities and higher regulatory approvals would be key growth drivers for the API industry, which is expected to report a high single-digit CAGR over the next 6-7 years.
There are immense opportunities that have emerged for API players such as Divi's Laboratories, as pharma giants across the world look to tide over the pandemic: Reuters